Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia
Jithma Abeykoon, MD, Mayo Clinic, Rochester, MN, discusses adverse events associated with BTK inhibitors (BTKis) in the treatment of Waldenström’s macroglobulinemia, with reference to his study comparing bendamustine and rituximab (BR) with ibrutinib in the frontline. He mentions atrial fibrillation and bleeding abnormalities as the main factors that lead to the discontinuation of BTKis. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Смотрите видео Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 29 Октябрь 2024, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 103 раз и оно понравилось 1 людям.